Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Live Birth Rate in Women with Recurrent Pregnancy Loss after In Vitro Fertilization with Concomitant Intravenous Immunoglobulin and Prednisone

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Feelings of guilt and loss of control dominate in stress and depression inventories from women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The untapped potential of reproductive history in cardiovascular disease

    Research output: Contribution to journalEditorialResearchpeer-review

View graph of relations

Pregnancy loss after in vitro fertilization (IVF) is at least as common as after spontaneous conception. Recurrent pregnancy loss (RPL) may often have an immunological background, and it is therefore relevant to test immune-based interventions in these patients. The objective was to investigate the effect of immunotherapy with intravenous immunoglobulin (IvIg) and prednisone (PRS) as concomitant therapy to IVF in women with RPL after earlier IVF treatments. In a cohort study conducted at The Danish RPL Clinic, 41 women with three or more consecutive pregnancy losses after IVF underwent at least one further IVF cycle with concomitant immunotherapy from 2012 to 2017. The immunotherapy with IvIg and PRS was given before embryo transfer and repeatedly in the first trimester when pregnancy was achieved. Fourteen women (34.2%) achieved a live birth after the first embryo transfer with immunotherapy, and a total of 32/41 (78%) achieved a live birth after up to 4 embryo transfers. Baseline characteristics and the presence of autoantibodies were not significantly different among women achieving live birth or not. The observed 34% birth rate in women with RPL after IVF receiving immunotherapy appears higher than the expected 16-19% birth rate without immunotherapy and is similar to findings in a previous cohort from our clinic. Concomitant immunotherapy as described may be a promising intervention for women with RPL after IVF; however, the effect must be tested in a randomized controlled trial.

Original languageEnglish
Article numberjcm11071894
JournalJournal of Clinical Medicine
Issue number7
Pages (from-to)1-10
Number of pages10
Publication statusPublished - 29 Mar 2022

    Research areas

  • intravenous immunoglobulin, IVF, prednisone, recurrent pregnancy loss

ID: 76294656